What is the impact of Helicobacter pylori density on the success of eradication therapy: A clinico-histopathological study

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 6, 2013, Pages 642-646

  Onal, Ibrahim Koral ^a   Gokcan, Hale ^a   Benzer, Emine ^a   Bilir, Gulay ^a   Oztas, Erkin ^a  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; TETRACYCLINE; UREA C 13; UREASE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL STRAIN; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PEPTIC ULCER; PROSPECTIVE STUDY; RAPID TEST; RAPID UREASE TEST; STOMACH; STOMACH ULCER; TREATMENT DURATION; TREATMENT RESPONSE; UREA BREATH TEST;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-INFECTIVE AGENTS; BREATH TESTS; CASE-CONTROL STUDIES; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; MALE; METRONIDAZOLE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; STOMACH; TETRACYCLINE; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84888433166     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.05.005     Document Type: Article

References (33)

1. Go M.F. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002, 16:3-15.
2. Brown L.M. Helicobacter pylori epidemiology and routes of transmission. Epidemiol Rev 2000, 22:283-297.
3. Frenck R.W., Clemens J. Helicobacter in the developing world. Microbes Infect 2003, 5:705-713.
4. Kusters J.G., van Vliet A.H., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006, 19:449-490.
5. Ernst P.B., Peura D.A., Crowe S.E. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006, 130:188-206.
6. Suerbaum S., Michetti P. Helicobacter pylori infection. N Engl J Med 2002, 347:1175-1186.
7. Onal I.K., Sokmensuer C., Onal E.D., Ersoy O., Yeniova O., Aydinli M., et al. Clinical and pathological features of nodular gastritis in adults. Turk J Med Sci 2009, 39:719-723.
8. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59:1143-1153.
9. Vakil N., Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007, 133:985-1001.
10. Malfertheiner P., Mégraud F., O'Morain C., Bell D., Bianchi Porro G., Deltenre M., et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht consensus report. The European Helicobacter pylori study group (EHPSG). Eur J Gastroenterol Hepatol 1997, 9:1-2.
11. Mégraud F. H.pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004, 53:1374-1384.
12. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
13. Padol S., Yuan Y., Thabane M., Padol I.T., Hunt R.H. The effect of CYP2C19 polymorphisms on H.pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006, 101:1467-1475.
14. Furuta T., Sugimoto M., Shirai N. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H.pylori. Aliment Pharmacol Ther 2007, 26:693-703.
15. Abdullahi M., Annibale B., Capoccia D., Tari R., Lahner E., Osborn J., et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008, 18:1450-1454.
16. Suzuki T., Matsuo K., Ito H., Sawaki A., Hirose K., Wakai K., et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006, 119:217-224.
17. Sheu B.S., Yang H.B., Su I.J., Shiesh S.C., Chi C.H., Lin X.Z. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 1996, 44:683-688.
18. Moshkowitz M., Konikoff F.M., Peled Y. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995, 36:845-847.
19. Perri F., Clemente R., Festa V. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol 1998, 30:146-150.
20. Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis, the updated Sydney system. Am J Surg Pathol 1996, 20:1161-1181.
21. Sepulveda A., Peterson L.E., Shelton J., Gutierrez O., Graham D.Y. Histological patterns of gastritis in H.pylori-infected individuals with a family history of gastric cancer. Am J Gastroenterol 2002, 97:1365-1370.
22. Tokunaga Y., Hata K., Ryo J., Kitaoka A., Tokuka A., Ohsumi K. Density of Helicobacter pylori infection in patients with peptic ulcer perforation. J Am Coll Surg 1998, 186:659-663.
23. Asante M., Ahmed H., Patel P., Davis T., Finlayson C., Mendall M., et al. Gastric mucosal hydrophobicity in duodenal ulceration: role of Helicobacter pylori infection density and mucus lipids. Gastroenterology 1997, 113:449-454.
24. Fiocca R., Villani L., Luinetti O., Gianatti A., Perego M., Alvisi C., et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol 1992, 420:489-498.
25. Yamamura F., Yoshikawa N., Akita Y., Mitamura K., Miyasaka N. Relationship between Helicobacter pylori infection and histologic features of gastritis in biopsy specimens in gastroduodenal diseases, including evaluation of diagnosis by polymerase chain reaction assay. J Gastroenterol 1999, 34:461-466.
26. Stolte M., Stadelmann O., Bethke B., Burkard G. Relationships between the degree of Helicobacter pylori colonisation and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995, 33:89-93.
27. Wagner S., Varrentrapp M., Haruma K., Lange P., Müller M.J., Schorn T., et al. The role of omeprazole (40mg) in the treatment of gastric Helicobacter pylori infection. Z Gastroenterol 1991, 29:595-598.
28. Miyake K., Tsukui T., Shinji Y., Shinoki K., Hiratsuka T., Nishigaki H., et al. Teprenone, but not H2-receptor blocker or sucralfate, suppresses corpus Helicobacter pylori colonization and gastritis in humans: teprenone inhibition of H.pylori-induced interleukin-8 in MKN28 gastric epithelial cell lines. Helicobacter 2004, 9:130-137.
29. Lai Y.C., Wang T.H., Huang S.H., Yang S.S., Wu C.H., Chen T.K., et al. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. World J Gastroenterol 2003, 9:1537-1540.
30. Vaira D., Zullo A., Vakil N., Gatta L., Ricci C., Perna F., et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. A randomized trial. Ann Intern Med 2007, 146:556-563.
31. Japan Rabeprazole Study group Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment Pharmacol Ther 2007, 25:1105-1113.
32. Sisson G., Goodwin A., Raudonikiene A., Hughes N.J., Mukhopadhyay A.K., Berg D.E., et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 2002, 46:2116-2123.
33. Varbanova M., Malfertheiner P. Bacterial load and degree of gastric mucosal inflammation in Helicobacter pylori infection. Dig Dis 2011, 29:592-599.